This inventor holds 5 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Novartis Ag. Active years: 2011-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2019
Title: The Innovative Contributions of Andreas Lerchner
Introduction
Andreas Lerchner is a notable inventor based in Binningen, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target critical biological pathways. With a total of five patents to his name, Lerchner's work has the potential to impact the treatment of various diseases.
Latest Patents
Lerchner's latest patents include innovative compounds such as oxazolidin-2-one-pyrimidine derivatives. These compounds serve as phosphatidylinositol-3-kinase (PI3K) inhibitors, which are crucial in the treatment of conditions dependent on PI3K. His invention details pharmaceutical compositions, methods for their manufacture, and their applications in treating diseases and disorders. Another significant patent involves purine derivatives that also act as PI3K inhibitors. This invention focuses on their preparation and medical use, particularly in treating cancer and neurodegenerative disorders.
Career Highlights
Throughout his career, Andreas Lerchner has worked with prominent companies in the pharmaceutical industry, including Novartis AG. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.
Collaborations
Lerchner has collaborated with esteemed colleagues such as Pascal Furet and Robin Alec Fairhurst. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile